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Aromatase excess syndrome (AEXS) is a rare autosomal
dominant disorder characterized by gynecomastia.
Although chromosomal inversions leading to abnormal
fusion between CYP19A1 coding exons and non-coding
exons of neighboring genes have been identified in a
few patients with AEXS, its molecular basis and clinical
spectrum remain largely unknown. We studied 18
affected males from six unrelated families A–F, and
found a heterozygous 79,156 bp tandem duplication
involving seven of 11 non-coding CYP19A1 exons 1 in
families A and B, a heterozygous 211,631 bp deletion
involving exons 2–43 of DMXL2 and exons 5–10 of
GLDN in family C, and a heterozygous 165,901 bp dele-
tion involving exons 2–43 of DMXL2 in families D–F.
Analysis of transcripts revealed that duplicated exons 1 at
the distal non-physiological position can also function as
transcription start sites, and that the two deletions pro-
duced the same chimeric mRNA constituted by DMXL2
exon 1 and CYP19A1 exons 2–10. Clinical features such
as gynecomastia and elevated estradiol/testosterone ratios
were milder in patients with duplications and deletions
than in those with inversions. Furthermore, genotype-
phenotype correlations in patients with duplications,
deletions, and inversions implies that phenotypic severity
of AEXS is primarily determined by the expression pat-
tern of CYP19A1 and the chimeric genes and by the
structural property of the fused exons with a promoter
function (i.e., the presence or absence of a natural trans-
lation start codon). The present study expands the
genetic mechanism and phenotypic spectrum of AEXS,
and provides novel models for genomic disorder leading
to gain-of-function mutations. We also discuss on the
effect of estradiol on the hypothalamic-pituitary gonado-
tropin control.
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